Publications

BRAF Apr 25 2025 Circulating tumor DNA analysis in patients with BRAF-mutated advanced unresectable solid tumors treated with plixorafenib (FORE8394/PLX8394) in Phase 1/2a study Read more

BRAF Apr 25 2025 FORTE: A Phase 2 Master Protocol Assessing Plixorafenib for BRAF-Altered Cancers Read more

BRAF Oct 21 2024 Activity of BRAF Inhibitor Plixorafenib (FORE8394) in Advanced Ovarian Cancer Harboring BRAF V600E Mutation Read more

BRAF Oct 17 2024 Safety & Efficacy of BRAF Inhibitor Plixorafenib in Children & Adults with Recurrent, BRAF altered PCNSTs Read more

BRAF Apr 17 2024 Paradox-Breaker BRAF inhibitor plixorafenib (FORE8394) synergizes with MEKi in BRAF V600 and non- V600 alterations Read more

BRAF Apr 17 2024 Efficacy of BRAF Inhibitor Plixorafenib (FORE8394) in Recurrent PCNST Read more

BRAF Apr 17 2024 Safety & Efficacy of BRAF Inhibitor FORE8394 Patients w. Advanced Solid & CNS Tumors Read more

BRAF Apr 16 2024 Dose optimization of novel BRAF inhibitor FORE8394 based on PK and efficacy results Read more

BRAF Sep 13 2022 Efficacy of BRAF Inhibitor FORE8394 in BRAF V600+ Patients Read more